Heart Sounds Measurement Using the Wearable Cardioverter Defibrillator (HS-WCD) Study
Status: | Completed |
---|---|
Conditions: | Cardiology |
Therapuetic Areas: | Cardiology / Vascular Diseases |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 11/15/2017 |
Start Date: | February 2016 |
End Date: | March 2016 |
Heart Sounds Measurement Using the Wearable Cardioverter Defibrillator (HS-WCD): Study Protocol
A prospective, validation study to evaluate the data accuracy of heart sounds recorded by the
LifeVest® Wearable Cardioverter Defibrillator (WCD). These data will be compared with the
heart sounds data recorded by an FDA-cleared device.
LifeVest® Wearable Cardioverter Defibrillator (WCD). These data will be compared with the
heart sounds data recorded by an FDA-cleared device.
To conduct a prospective, validation study to evaluate the data accuracy of heart sounds
recorded by the LifeVest® Wearable Cardioverter Defibrillator (WCD). To show equivalence,
these data will be compared with the heart sounds data recorded by an FDA-cleared device.
The study will enroll a minimum of 27 and a maximum of 35 subjects.
Participants will be adult patients (age ≥ 18 years) with at least seven patients over the
age of 40 years. In addition, at least five patients with a history of heart failure will be
included.
First, participants will wear the FDA-cleared device for 15 minutes while sitting quietly.
Then, the FDA-cleared device will be removed and the participants will wear the WCD for 15
minutes while sitting quietly. Next, while wearing the WCD, participants will perform various
activities of daily living, including at least 6 hours of overnight wear. Finally, the WCD
will be removed and the participants will wear the FDA-cleared again for 15 minutes while
sitting quietly.
This is a single center, prospective, observational study. This is a non-significant risk
device study as all biological study parameters will be measured noninvasively with the WCD
defibrillation capability disabled. In addition, the study device will not be used as a
replacement for regularly prescribed therapies or diagnostics.
recorded by the LifeVest® Wearable Cardioverter Defibrillator (WCD). To show equivalence,
these data will be compared with the heart sounds data recorded by an FDA-cleared device.
The study will enroll a minimum of 27 and a maximum of 35 subjects.
Participants will be adult patients (age ≥ 18 years) with at least seven patients over the
age of 40 years. In addition, at least five patients with a history of heart failure will be
included.
First, participants will wear the FDA-cleared device for 15 minutes while sitting quietly.
Then, the FDA-cleared device will be removed and the participants will wear the WCD for 15
minutes while sitting quietly. Next, while wearing the WCD, participants will perform various
activities of daily living, including at least 6 hours of overnight wear. Finally, the WCD
will be removed and the participants will wear the FDA-cleared again for 15 minutes while
sitting quietly.
This is a single center, prospective, observational study. This is a non-significant risk
device study as all biological study parameters will be measured noninvasively with the WCD
defibrillation capability disabled. In addition, the study device will not be used as a
replacement for regularly prescribed therapies or diagnostics.
Inclusion Criteria:
- Healthy male and female volunteers who are able to fit in the WCD garment (26 to 56
inches measured circumferentially at the level of the xiphoid process).
- Included in this group are at least five healthy subjects with a self-reported history
of heart failure.
- The subject must be 18 years of age or older on the day of screening, with at least 7
subjects 40 years of age or older on the day of screening.
Exclusion Criteria:
- Mental, visual, physical, literacy, and auditory limitations that prevent interaction
with the WCD equipment.
- Any acute medical conditions that prevent the following maneuvers: lying on back,
lying on the right and left side, standing, sitting, and/ or leaning forward when
sitting.
- Any self-reported shortness of breath, fatigue, swelling of feet, ankles, or legs,
and/or chest pain
- Employees or family members of the sponsor.
- Unable or unwilling to provide written informed consent.
We found this trial at
1
site
Click here to add this to my saved trials